echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Nuocheng Jianhua will bring its innovation pipeline to the 2021 Service Trade Fair to help healthy China

    Nuocheng Jianhua will bring its innovation pipeline to the 2021 Service Trade Fair to help healthy China

    • Last Update: 2021-09-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    2021 China International Service Trade Fair (MAST will) will be held September 2 - 7 days at the National Convention Center and Beijing Shougang Park held Connaught-China (SEHK: 09969) will be unveiled Shougang Park 5 Hall No.


    From September 2nd to 7th, Shougang Park Hall No.


    Nuocheng Jianhua will exhibit the special achievements of the national "Major new drug creation"

    Obrutinib (product name: Inokia) is a class 1 innovative drug independently developed by Nuocheng Jianhua.


    Obrutinib (product name: Inokia) is a class 1 innovative drug independently developed by Nuocheng Jianhua.


    Comprehensive layout of hematoma

    Comprehensive layout of hematoma

    Nuocheng Jianhua has in-depth layout of hematoma and intensified its efforts to develop new drugs to better benefit patients with hematoma


    In addition, Nuocheng Jianhua also owns ICP-B02 (CM355), ICP-248 and ICP-490.


    The treatment of solid tumors is promising

    The treatment of solid tumors is promising

    Nuocheng Jianhua focuses on the development of new drugs for malignant solid tumors, and is currently developing innovative small and macromolecular drugs to overcome various solid tumors


    In addition, Nuocheng Jianhua also owns ICP-189 and ICP-B03.


    Autoimmune diseases, key breakthroughs

    Autoimmune diseases, key breakthroughs

    Nuocheng Jianhua focuses on the development of new drugs in the field of autoimmune diseases, bringing new treatment options to these patients


    In addition, the new TYK2 inhibitor ICP-332 has entered the clinic and will be used to treat T cell-related immune diseases such as psoriasis and atopic dermatitis


    The Service Trade Fair Health Service Special Exhibition aims to showcase China's medical technology innovation level, medical product innovation results, medical service innovation capabilities and health service development quality to the world, and promote the expansion of the health industry and the development of cross-border emerging pharmaceutical trade


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.